Melissa M Berrien-Elliott

18PUBLICATIONS
129CO-AUTHORS
Haematological tumoursInnate immunityMolecular targetsGene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (18)

|Mar 25, 2026
Reduced Tumor Control in Males Can Result from Impaired CD4+ T-cell Help through the CD40L-CD40 Pathway.

Katey S Hunt, Samantha Cooke, Lindsey M Kuehm

|Jan 23, 2025
First-in-Human Phase I Study of a CD16A Bispecific Innate Cell Engager, AFM24, Targeting EGFR-Expressing Solid Tumors.

Anthony El-Khoueiry, Omar Saavedra, Jacob Thomas

|Aug 09, 2023
Memory-like Differentiation, Tumor-Targeting mAbs, and Chimeric Antigen Receptors Enhance Natural Killer Cell Responses to Head and Neck Cancer.

Miriam T Jacobs, Pamela Wong, Alice Y Zhou

|Jul 03, 2023
Anti-myeloma efficacy of CAR-iNKT is enhanced with a long-acting IL-7, rhIL-7-hyFc.

Julie O'Neal, Matthew L Cooper, Julie K Ritchey

|May 02, 2023
Costimulatory domains direct distinct fates of CAR-driven T-cell dysfunction.

Mehmet Emrah Selli, Jack H Landmann, Marina Terekhova

|Nov 23, 2022
Allogeneic natural killer cell therapy.

Melissa M Berrien-Elliott, Miriam T Jacobs, Todd A Fehniger

Pageof 3

Frequent Collaborators

12 joint publications

Todd A Fehniger

7 joint publications

Pamela Wong

6 joint publications

Jennifer A Foltz

5 joint publications

Miriam T Jacobs